Legal & General Group Plc Invests $1.74 Million in Certara, Inc. $CERT

Legal & General Group Plc bought a new position in shares of Certara, Inc. (NASDAQ:CERT) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 265,727 shares of the company’s stock, valued at approximately $1,741,000. Legal & General Group Plc owned about 0.17% of Certara as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of CERT. Northwestern Mutual Wealth Management Co. raised its position in shares of Certara by 2,733.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock worth $26,000 after acquiring an additional 2,870 shares in the last quarter. Osaic Holdings Inc. grew its stake in Certara by 50.7% during the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after purchasing an additional 1,175 shares during the period. Tower Research Capital LLC TRC grew its stake in Certara by 499.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock worth $69,000 after purchasing an additional 4,930 shares during the period. State of Wyoming bought a new stake in Certara in the second quarter worth approximately $72,000. Finally, Pacer Advisors Inc. increased its holdings in Certara by 28.1% in the first quarter. Pacer Advisors Inc. now owns 13,093 shares of the company’s stock worth $75,000 after purchasing an additional 2,871 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Price Performance

Shares of NASDAQ:CERT opened at $7.94 on Monday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.55 and a current ratio of 2.55. Certara, Inc. has a 52-week low of $4.45 and a 52-week high of $13.88. The business’s 50 day simple moving average is $7.63 and its two-hundred day simple moving average is $6.52. The firm has a market cap of $1.21 billion, a P/E ratio of -17.64 and a beta of 1.40.

Certara (NASDAQ:CERT) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. The business had revenue of $93.27 million during the quarter, compared to analyst estimates of $98.09 million. During the same period in the previous year, the business posted $0.07 EPS. The business’s revenue for the quarter was down 10.8% compared to the same quarter last year. As a group, research analysts forecast that Certara, Inc. will post 0.22 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have issued reports on CERT. Robert W. Baird cut their price target on Certara from $7.00 to $6.00 and set a “neutral” rating on the stock in a report on Tuesday, May 12th. Weiss Ratings upgraded shares of Certara from a “sell (e+)” rating to a “sell (d)” rating in a research report on Wednesday, August 5th. Stephens dropped their target price on shares of Certara from $10.00 to $9.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Morgan Stanley cut their target price on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. Finally, BMO Capital Markets reduced their price target on shares of Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a report on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $8.28.

Certara Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.